The Generic Submissions Under Review (GSUR) list is a list of Abbreviated New Drug Submissions (generic submissions) that were accepted into review on or after October 1, 2018 and is intended to be updated on a monthly basis. The list currently includes the medicinal ingredient(s), therapeutic area and number of submissions under review. On January 7, 2019, Health Canada published a Notice soliciting feedback on possible impacts and uses to stakeholders if the GSUR list is updated to include sponsor names (i.e., the company that filed the generic submission).
Sponsors are included in the Submissions Under Review List for new drug submissions (which includes biosimilars) accepted into review on or after October 1, 2018. Stakeholder feedback should be submitted by email to Health Canada by February 8, 2019.
Related Publications & Articles
-
Health Canada releases notice on aligned reviews between Health Canada and health technology assessment organizations
On November 5, 2024, Health Canada released the Notice to industry: Aligned reviews between Health Canada and health technology assessment organizations.Read More -
Health Canada posts 2023 to 2024 review on drug shortages
On November 20, 2024, Health Canada posted Drug shortages in Canada: Fiscal year 2023 to 2024 in review.Read More -
Agile licensing amendments registered
Following consultation starting in 2022, on November 29, 2024, Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing) were registered.Read More